Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.

Nature communications - 19 Apr 2022

Lee Hyo-Jung, Song Kwon-Ho, Oh Se Jin, Kim Suyeon, Cho Eunho, Kim Jungwon, Park Yun Gyu, Lee Kyung-Mi, Yee Cassian, Song Seung-Hwa, Chang Suhwan, Choi Jungmin, Jung Sang Taek, Kim Tae Woo

Abstract excerpt

Immunotherapy has emerged as a powerful approach to cancer treatment. However, immunotherapeutic resistance limits its clinical application. Therefore, identifying immune-resistant factors, which can be targeted by clinically available drugs and it also can be a companion diagnostic marker, is needed to develop combination strategies. Here, using the transcriptome data of patients, and immune-refractory tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Immunotherapy

Share to Phenotype

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35440620
DOI: 10.1038/s41467-022-29611-y
PMCID: PMC9019109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.PMID 35440620Read ↗

Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.Semantic proximity Read ↗

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy ResistanceSemantic proximity Read ↗

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Semantic proximity Read ↗

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapySemantic proximity Read ↗

New Insights into Therapy-Induced Progression of CancerSemantic proximity Read ↗

The Role of Long Non-coding RNAs in Immunotherapy ResistanceSemantic proximity Read ↗

Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.Semantic proximity Read ↗

The Resistance Mechanisms of Checkpoint Inhibitors in Solid TumorsSemantic proximity Read ↗

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphomaSemantic proximity Read ↗

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune EvasionSemantic proximity Read ↗

Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphomaSemantic proximity Read ↗

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade RespondersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.